AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2020
Aug 28, 2020
31289_dirs_2020-08-27_71d33424-80e9-4f46-9c94-633308e31f4d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Viking Therapeutics, Inc. (VKTX)
CIK: 0001607678
Period of Report: 2020-08-25
Reporting Person: LIGAND PHARMACEUTICALS INC (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-08-25 | Common Stock | S | 70000 | $8.0225 | Disposed | 5968083 | Direct |
| 2020-08-26 | Common Stock | S | 94488 | $8.108 | Disposed | 5819383 | Direct |
Footnotes
F1: Includes 882,474 shares of Common Stock held by Metabasis Therapeutics, Inc., a wholly owned subsidiary of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.0948 to $8.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.